Stoessl A J
Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada.
Neuropharmacology. 1995 Apr;34(4):457-62. doi: 10.1016/0028-3908(94)00163-m.
The role of neurotensin (NT) in a putative model of tardive dyskinesia (TD) was examined in the rat. When administered directly into the ventrolateral striatum of neuroleptic-naive animals, NT (2.5 micrograms/side) elicited vacuous chewing movements. This response was not seen following administration of NT into other striatal regions or the substantia nigra and was suppressed by the NT antagonist SR 48692 (100 micrograms/kg i.p.). Vacuous chewing movements were also seen following chronic administration of fluphenazine decanoate. These movements were likewise suppressed by SR 48692 (10-100 micrograms/kg i.p.), which failed to affect other behavioural responses and was without effect in neuroleptic-naive animals. Our data suggest that increased levels of endogenous NT within the ventrolateral striatum may play a critical role in the development of TD following chronic neuroleptic administration and that NT antagonists may be beneficial for the treatment of this disorder.
在大鼠中研究了神经降压素(NT)在迟发性运动障碍(TD)假定模型中的作用。当直接注射到未使用过抗精神病药物动物的腹外侧纹状体时,NT(2.5微克/侧)引发了空嚼运动。将NT注射到其他纹状体区域或黑质后未观察到这种反应,并且该反应被NT拮抗剂SR 48692(100微克/千克腹腔注射)抑制。长期给予癸酸氟奋乃静后也观察到了空嚼运动。这些运动同样被SR 48692(10 - 100微克/千克腹腔注射)抑制,而SR 48692对其他行为反应没有影响,且对未使用过抗精神病药物的动物无效。我们的数据表明,腹外侧纹状体内内源性NT水平的升高可能在长期使用抗精神病药物后TD的发生中起关键作用,并且NT拮抗剂可能对这种疾病的治疗有益。